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Abstract: The human pregnane X receptor (PXR) is a member of the nuclear receptor superfamily
of ligand-regulated transcription factors. PXR responds to a structurally diverse variety of
endogenous and xenobiotic compounds, and coordinates the expression of genes central to the
metabolism and excretion of potentially harmful chemicals, including human therapeutics. The
reverse transcriptase inhibitor PNU-142721 has been designed to treat human immunodeficiency
virus (HIV) infection. Although this compound has anti-HIV activity, it was established using
cell-based assays that PNU-142721 is an efficacious PXR agonist. We present here the 2.8 Å
resolution crystal structure of the human PXR ligand-binding domain in complex with
PNU-142721. PXR employs one hydrogen bond and fourteen van der Waals contacts to interact
with the ligand, but allows two loops adjacent to the ligand-binding pocket to remain disordered
in the structure. These observations highlight the role structural flexibility plays in PXR’s
promiscuous responses to xenobiotics. The crystal structure also explains why PNU-173575,
a thiomethyl metabolite of PNU-142721, exhibits enhanced PXR activation relative to the
unmodified compound and why PNU-142721 can also activate rat PXR. Taken together, the
results presented here elucidate the structural basis for PXR activation by PNU-142721 and
related chemicals.
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Introduction
Nucleoside (or nucleotide) reverse transcriptase
inhibitors (NRTIs) and non-nucleoside (or nucleo-
tide) reverse transcriptase inhibitors (NNRTIs) are
the two popular types of anti-HIV drugs that target
reverse transcriptase (RT).1 NRTIs directly bind to
the catalytic site of RT and competitively inhibit
enzyme activity, while NNRTIs bind to an allosteric
lipophilic site adjacent to the catalytic site of RT and
function in a noncompetitive manner.2 Due to their
distinct mechanisms, NRIs and NNRTIs are
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commonly used together in HIV treatment regimen
to achieve optimal efficacy.3,4 Like other antiviral
drugs, the usefulness of anti-HIV drugs is often com-
promised by mutations in the drug binding sites of
HIV RT, which arise quickly due to the high muta-
tion rate of the virus.5 Over the past two decades,
the design of new drugs that can efficiently treat
drug-resistant HIV has become a significant chal-
lenge.6 Indeed, the combinational use of multiple
anti-HIV drugs with distinct mechanisms of action,
such as the triple-cocktail treatment, has thus-far
been proven to be the most effective anti-HIV regi-
men available.7
A fundamental problem associated with coad-
ministering multiple drugs is the risk of drug–drug
interactions. Cytochrome P450 (CYP) enzymes have
been shown to be centrally involved in such interac-
tions due to the principal role these proteins play in
eliminating potentially toxic xenobiotics.8 The nu-
clear receptor pregnane X receptor (PXR) is a mas-
ter regulator of the expression of CYP enzymes
involved in drug metabolism. PXR is the primary
sensor of xenobiotic stress in the liver and other
first-pass tissues and can be activated by a struc-
turally diverse collection of molecules including
many drugs.9,10 Like other nuclear receptors, PXR
contains a DNA binding domain (DBD), a ligand-
binding domain (LBD), and a flexible linker
domain.10 The PXR-LBD consists of a three-layered
a-helical sandwich, common to nuclear receptors
and a five-stranded antiparallel a-sheet, unique to
PXR.11–16 The PXR-DBD binds specifically to the
DNA response elements in the regulatory regions of
CYP genes as a heterodimer with the retinoid X re-
ceptor (RXR).9 Upon activation by ligand binding to
the LBD, PXR recruits coactivators that facilitate
the formation of the transcriptional initiation com-
plex and the expression of CYP gene products.9
Coactivator proteins bind to the activation function
2 (AF-2) region of the PXR-LBD using a surface
formed, in part, by the C-terminal aAF helix in the
receptor.17
PNU-142721 was first identified as a broad-
spectrum second-generation NNRTI that demon-
strated potent efficacy against various type I HIV
mutants resistant to first-generation antivirals like
delavirdine and zidovudine18 (Fig. 1). Despite its
promising in vitro performance, studies showed that
PNU-142721 causes strong drug–drug interactions
by activating PXR (unpublished data from Dr. Evan
Smith). We elucidate here the structure basis for
PNU-142721 mediated PXR activation by solving the
crystal structure of PXR-LBD in complex with PNU-
142721.
Results
PXR-PNU142721 complex crystal structure
To understand the structural basis of receptor acti-
vation by this potential therapeutic lead, we deter-
mined the crystal structure of the human PXR-LBD
in complex with PNU-142721. One protein-ligand
complex was observed in each asymmetric unit. The
structure was determined by molecular replacement
in space group P43212 and refined to 2.8 Å resolu-
tion [Fig. 2(A) and Table I]. The PXR-LBD in this
complex consists of a three-layered a-helical sand-
wich (a1/a3, a4/a5/a8, and a7/a10) common to nu-
clear receptors and a five-stranded antiparallel b-
sheet unique to PXR [Fig. 2(A)]. Three regions
located adjacent to the ligand-binding pocket (the
loops 176–198 and 309–315, as well as residue 217)
are disordered and not built in the final model (Fig.
3). The region between residues 176 and around 198
have been reported to be disordered in other PXR-
LBD structures resolved to date.11–17 The PXR-
PNU142721 complex exhibits the same overall fold
observed in previous PXR structures, sharing, for
example, 0.22 Å root-mean-square deviation over
254 Ca positions with the structure of the unli-
ganded PXR-LBD.15 Of note, this is the second
structure of PXR in which the 309–315 loop of the
ligand binding domain remains disordered. The first
was the complex with the much larger rifampicin
ligand.16 Thus, we find that even relatively small
ligands allow PXR’s ligand binding pocket to remain
flexible.
Figure 1. Chemical Structures of PNU-142721 and its
metabolite PNU-173575.
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PNU-142721 binding to PXR-LBD
A 2.8 Å simulated annealing omit map contoured at
2.5 r was used to identify the electron density for
PNU-142721, which binds to the PXR ligand-binding
pocket in a single orientation [Fig. 2(B)]. PNU-
142721 forms van der Waals contacts with the side
chains of 14 residues that line the ligand-binding
pocket [Fig. 2(C)]. In addition, the side-chain amine
group of Gln-285 forms a 3.3 Å, presumably weak
hydrogen bond with the nitrogen atom of the furo-
pyridine ring of PNU-142721 [Fig. 2(C)]. As observed
in other complexes, van der Waals contacts play a
principal role in stabilizing PNU-142721 within
PXR’s ligand-binding pocket. Phe-288 forms a paral-
lel aromatic stacking interaction with the furopyri-
dine ring of PNU-142721, while Trp-299 and Tyr-306
form edge-to-face aromatic stacking contacts with
the same ligand ring. The pyrimidine ring of PNU-
142721 forms van der Waals interactions with the
side chain of eleven residues, including a 3.6 Å inter-
action with Met-425 and a 5.0 Å interaction with
Phe-429, which are located on aAF of the PXR AF-2
surface. These interactions likely help to stabilize
the active conformation of the AF-2 surface for coac-
tivator binding.
PNU142721 metabolite binding to PXR-LBD
PNU-173575, a thiomethyl metabolite of PNU-
142721, is a more potent activator of PXR than the
unmodified compound (unpublished data from
Dr. Evan Smith). As shown in Figure 1, the only dif-
ference between these two compounds is that the
Figure 2. Crystal structure of the human PXR-LBD in complex with PNU-142721. (A) The overall structure of PXR-LBD in
complex with PNU-142721. The a-helices, b-strands and loops are rendered in cyan, magenta, and gray, respectively.
PNU-142721 is colored by elements, with green, red, blue, yellow and magenta representing carbon, oxygen, nitrogen sulfur
and chlorine atoms, respectively. Note the proximity of the PNU-142721 to aAF of the AF-2 surface of PXR. (B) The 2.8 Å
simulated annealing omit map contoured at 2.5 r is shown in blue mesh. PNU-142721 is shown and colored by elements.
(C) Stereoview of the ligand-binding pocket of the PXR-PNU142721 complex. Residues that line the ligand-binding pocket of
PXR are shown in gray and labeled. The hydrogen bond is represented by a red dash line. [Color figure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
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chloro group on the pyrimidine ring of PNU-142721
is replaced by a thiomethyl group in PNU-173575.
To understand why this small change improves
PNU-173575 PXR activation, we modeled PNU-
173575 into PXR’s ligand-binding pocket using the
structure of PNU142721 as a template (Fig. 4). To
accommodate PNU-173575, the side chain of Leu-
411 and His-407 were shifted by favored rotamers by
alterations of 100.3 and 88.5, respectively (Fig. 4).
Although the rotamer change in His-407 is likely to
cause the loss of a 4.8 Å van der Waals contact
between the ligand and PXR, two new van der
Waals contacts are observed between the thiomethyl
group and the side chain of residues that are located
on the aAF of the PXR AF-2 surface, including a 3.9
Å contact with Met-425, and a 4.1 Å contact with
Phe-429. Thus, these new van der Waals contacts
likely explain the improved PXR activation of PNU-
173575, as they are better able to stabilize the active
conformation of receptor’s AF-2 surface.
Modeling of the structure of rat PXR-LBD in
complex with PNU-142721
PNU-142721 can induce PXR-mediated CYP3A
expression in rats (unpublished data from Dr. Evan
Smith). Due to the relatively high sequence similar-
ity (76% identity) shared between the rat and
human PXRs, the rodent receptor is expected to
have a structure highly analogous to human PXR.
To understand rat PXR activation by PNU-142721,
we modeled the structure of the ligand-binding
pocket of rat PXR based on the structure of human
PXR. The following five residues that interact with
PNU-142721 in human PXR were altered to the cor-
responding residue (listed second) in the rat
sequence: Leu209Met, Met243Leu, Met246Val,
Gln285Ile and His407Gln (Fig. 5). Because they are
largely conservative with respect to amino acid type,
no significant change in the interaction between
PNU-142721 and the PXR-LBD was observed in this
modeled binding pocket. Indeed, PNU-142721 still
forms 14 van der Waals contacts with residues that
line the ligand binding pocket of rat PXR. Thus, for
this particular lead scaffold, rat PXR served as an
excellent model for potential activation of human
PXR.
Table I. Crystallographic Statistics for the
PXR-PNU142721 Complex
Resolution (Å) (highest shell) 41.3–2.8 (2.87–2.80)
Space group P43212
Unit cell dimension (Å) a¼b¼ 92.3, c ¼ 84.4
No. of total reflections 9394
No. of unique reflections 8944
Rsym (%) (highest shell)
a 9.4 (53.0)
Completeness (%) (highest shell) 99.5 (96.9)
Mean I/r (highest shell) 42.0 (5.1)
Rcryst (%) (highest shell)
b 23.8 (27.6)
Rfree (%) (highest shell)
c 28.9 (42.8)
RMSD
Bond lengths (Å) 0.033
Bond angles () 2.5





a Rsym ¼ RjI  hIij=RI where I is the observed intensity
and hIi is the average intensity of multiple symme-
try-related observation of the reflection.
b Rcryst ¼ RjjFobsj  jFcalcjj=RjFobsj where Fobs and Fcalc
are the observed and calculated structure factors,
respectively.
c Rfree ¼ RjjFobsj  jFcalcjj=RjFobsj for 5% of the data not
used at any stage of the refinement.
Figure 3. Analysis of the ligand binding pocket of PXR-LBD-PNU complex. Stereoview of a superimposition between the
apo-PXR (blue), PXR-PNU142721 (green) and PXR-rifampicin (red) complexes. Major secondary structures around the ligand-
binding pocket are labeled. The hydrogen bond is represented by a red dash line. [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
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Discussion
As the use of anti-HIV drug cocktails becomes
increasingly necessary, dangerous drug–drug inter-
actions may emerge as a major challenge in the anti-
retroviral field. Studies showed that potent HIV-1
RT inhibitor PNU-142721 produced drug–drug inter-
actions, although the underlying mechanisms
remained elusive. It has been shown that PNU-
142721 activates the nuclear xenobiotic receptor
PXR in a concentration-dependent manner and
PNU-173575, the metabolite of PNU-142721, is a
better PXR-agonist than PNU-142721 (unpublished
data from Dr. Evan Smith). Altogether, these results
established that PNU-142721 is an efficacious PXR
agonist and it likely causes drug–drug interactions
by activating PXR.
We elucidated the crystal structure of the PXR-
LBD in complex with PNU-142721. The mechanism
of ligand-induced PXR activation has been well stud-
ied by X-ray crystallography and other techniques.
To activate PXR, a ligand needs to bind to the
ligand-binding pocket of PXR and form direct inter-
actions with the aAF helix, thereby stabilizing the
AF-2 surface in the active conformation.10 Due to
the large size and flexibility of the PXR’s ligand
binding pocket, however, it has been difficult to pre-
dict the exact binding mode of a novel ligand in
PXR’s ligand binding pocket by known PXR struc-
tures, although recent studies have demonstrated
progress in this regard.19 Our PXR-PNU-142721
complex crystal structure reveals that van der Waals
interactions play a major role in stabilizing the
interaction between drug and receptor [Fig. 2(C)].
PNU-142721 forms van der Waals contacts with 14
residues in PXR’s ligand-binding pocket, which cov-
ers all of five ligand-binding hot spots recently iden-
tified by Ngan et al,20 indicating a strong affinity
between PNU-142721 and PXR. As in previous PXR-
ligand structures, Gln-285 is found to form a hydro-
gen bond with the ligand, indicating its conserved
role in ligand interaction. PNU-142721 forms direct
van der Waals contacts with Met-425 and Phe-429,
which are located on the aAF helix. The contact
with Met-425 has been commonly observed in previ-
ous published PXR-ligand structures, while the con-
tact with Phe-429 only appears in the PXR-estradiol
structure to date.
The crystal structure of the PXR-PNU142721
complex was then used to examine two recent obser-
vations: (1) the thiomethyl metabolite PNU-173575
Figure 4. Modeled structure of human PXR-LBD in complex with PNU-173575. Residues that line the PXR ligand binding
pocket are shown in gray, except for His-407 and Leu-411 which undergo rotamer changes in the presence of PNU-173575.
The side-chain position of His-407 and Leu-411 in the presence of PNU-142721 and PNU-173575 are represented in blue
and magenta, respectively. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
Figure 5. Modeled structure of rat PXR-LBD in complex with PNU-142721. Residues that line rat PXR ligand binding pocket
and are conserved between human PXR and rat PXR are labeled and colored in gray, while residues that differ between
human PXR and rat PXR are highlighted in orange (rat PXR) and magenta (human PXR), respectively. PNU-142721 is colored
by elements, with green, red, blue, yellow and cyan representing carbon, oxygen, nitrogen sulfur and chlorine atoms,
respectively. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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exhibits improved PXR activation relative to PNU-
142721 and (2) PNU-142721 is also an agonist for
rat PXR (unpublished data from Dr. Evan Smith).
First, we found that the modeled structure of PNU-
173575 in PXR’s ligand binding pocket indicates
that 173575 can bind to PXR in a similar way as
PNU-142721. By means of the longer and more
hydrophobic thiomethyl group, PNU-173575 appears
capable of forming improved interactions with the
aAF helix, and thereby stabilize the AF-2 surface in
an active conformation. Second, the ligand-binding
pocket of rat PXR can be modeled simply by mutat-
ing five residues in human PXR to their counter-
parts in rat PXR. Despite several changes in rele-
vant residues, key ligand interactions are conserved
between human PXR and rat PXR, indicating that
rat PXR can bind PNU-142721 in a similar way to
human PXR. Our results reinforce the hypothesis
that, in this particular case, the rat could be used as
a good model for the prediction of potential drug–
drug interaction in human.
If one wanted to modify PNU-142721 to elimi-
nate its activation of PXR, the crystal structure of
the complex could be used as a guide. The van der
Waals interaction between the chloro-group on the
pyrimidine ring of PNU-142721 and the aAF helix of
PXR appear key to the stabilization of AF-2 surface
in the active conformation. Therefore, disrupting the
interaction between PNU-142721 and the AF-2 sur-
face could be achieved by removing the chloro-group
from the pyrimidine ring. However, previous studies
have shown that the pyrimidine thioether moiety is
the major anti-HIV pharmacophore of PNU-
142721.18 The furopyridine moiety, however, was not
as important,18 and thus, it might be safer to disrupt
the interaction between PNU-142721 and PXR by
modifying this ring. As observed in the complex
structure, the furopyridine ring of PNU-142721
interacts with five residues in the ligand-binding
pocket including Phe-288, Trp-299, Tyr 306, His-327,
and Gln-285. Among these contacts, the p–p interac-
tion between the side-chain of Phe-288 and the furo-
pyridine ring provide the major stabilizing forces,
keeping the furopyridine ring in the current orienta-
tion. Disruption of this interaction by introducing a
bulky group on the C2 atom of the ligand (see Fig.
1), which is spatially closest to Trp-299 (see Fig. 5),
may effectively destabilize the interaction of PNU-
142721 with PXR. Either PNU-142721 or Trp-299
would have to move to accommodate this bulky
group. Trp299 is located on four-stranded b-sheet,
which is known for its rigidity and does not change
its conformation even upon the binding of large PXR
ligands like rifampcin. Therefore, it is not likely that
Trp-299 would adjust its position to accommodate
the bulky group. Also, there is no observable space
around Trp-299 for its side-chain to take alterative
rotamers to accommodate the bulky group. There-
fore, it would be expected that PNU-142721 might
move away from Trp-299 toward the other side of
the ligand-binding pocket. This movement will break
three important interactions between PXR and the
furopyridine ring of PNU-142721, including the p–p
interaction with Phe-288, the van der Waals interac-
tion with Tyr-306, and the hydrogen bonding with
the side chain of Gln-285. Although several new van
der Waals interactions might form meanwhile, they
are not likely to compensate for the losses mentioned
above. Taken together, the proposed modification
here might mitigate PXR agonist activity by disrupt-
ing the binding of PNU-142721 to PXR.
In summary, the data presented here reveal the
detailed mechanism of PNU-142721-mediated PXR
activation. Using the structural model presented
here, we explained why the metabolite PNU-173575
is a better PXR agonist and why PNU-142721 can
also activate rat PXR. Based on the structural data
presented here, several routes toward the redesign
of PNU-142721 were proposed that may limit PXR
activation while keeping intact the HIV-1 RT inhibi-
tory activity of this compound.
Materials and Methods
Protein expression and purification
The human PXR-LBD (residues 130–434) was coex-
pressed with an 88-amino acid fragment of human ste-
roid receptor coactivator 1 (SRC-1) (623–710) in E. coli
and purified as described previously.15 Purified hPXR-
LBD was concentrated to 3 mg/mL in buffer contain-
ing 20 mM Tris-HCl (pH 7.8), 250 mM NaCl, 5 mM
DTT, 2.5 mM EDTA and 5% Glycerol (v/v) using a
Centri-prep 30K unit (Amicon) in the presence of 20-
fold molar excess PNU-142721. Purified protein was
flash-frozen using liquid nitrogen and stored at80C.
Crystallization, data collection, and structural
determination
The hPXR-PNU142721 complex was crystallized by
hanging-drop vapor diffusion at room temperature
against 50 mM imidazole (pH 7.8) and 16% 2-propa-
nol (v/v). Crystals were handled for cryoprotection as
described previously.15 Data collection was con-
ducted at SER-CAT at the Advanced Photon Source
in Argonne National Labs (Beamline 22-ID). Diffrac-
tion data were indexed, integrated and scaled using
HKL2000.21 The structure of hPXR-PNU142721
complex was determined by molecular replacement
with the MolRep module of the CCP4 suite22,23 using
the crystal structure of the apo PXR as the search
model. Clear rotational and translational solutions
were obtained in space group P43212. The structure
was manually adjusted using WinCoot 3.1,24 and
refined using the Refmac module of CCP4,25 with
5% of the reflections set aside for Rfree validation
before any structural refinement. Simulated
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annealing omit map was generated using the pro-
gram CNS.26 All the molecular graphic figures in
this work were created using Pymol.27 While the
electron density alone was not sufficient to distin-
guish unambiguously the position of the chlorine
and the primary amine of the pyrimidine ring, they
were modeled based on the following reasoning. It
has been well established that, to activate PXR, a
ligand must stabilize the AF-2 surface in the active
conformation by forming direct hydrophobic interac-
tions with the aAF helix. Therefore, we placed the
more hydrophobic chlorine toward the aAF helix.
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